Search

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

Confronting health disparities in clinical trials

As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.

Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US

Read more about Dr. Steven Wolchinsky receiving the first Vetmedin® (pimobendan) Cardiology Pioneer award, for his work and commitment to animal health.

Boehringer’s unique approach to innovation

Boehringer’s unique approach to driving patient-centric innovation

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

U.S. FDA grants Breakthrough Therapy designation for MASH

Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis

Boehringer inhalers now available at $35 a month for eligible patients

Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

Building Successful Partnerships in Animal Health

Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.

Improving Access to Clinical Trials

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Boehringer welcomes 2023 Gold Report

Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

PI Update for Pradaxa® (dabigatran etexilate) | BI US

Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Express Scripts Adds BI Products to Roster | BI US

Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Confronting health disparities in clinical trials

Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US

Boehringer’s unique approach to innovation

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

U.S. FDA grants Breakthrough Therapy designation for MASH

Boehringer inhalers now available at $35 a month for eligible patients

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

Building Successful Partnerships in Animal Health

Improving Access to Clinical Trials

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Boehringer welcomes 2023 Gold Report

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

PI Update for Pradaxa® (dabigatran etexilate) | BI US

S&P Animal Health Partnering Oct 2023

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Express Scripts Adds BI Products to Roster | BI US

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

Interchangeable Biosimilar Now on Express Scripts® Formulary

Low-WAC interchangeable biosimilar is now available

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)